NCT07109479尚未招募不适用
A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the Single-Use Coronary Forward Intravascular Lithotripsy Catheter Combined With the Intravascular Lithotripsy Therapy Device for Pre-treatment of De Novo Calcified Stenotic Coronary Lesion
Spectrumedics Medical Technology(Shanghai)Co.,Ltd1 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2025年10月1日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 180
- 试验地点
- 1
- 主要终点
- Rate of Device Success
研究概览
简要总结
The FORWARD IVL trial is a Prospective, Multicenter Study conducted to assess the safety and effectiveness of the Single-Use Coronary Forward Intravascular Lithotripsy Catheter combined with the Intravascular Lithotripsy Therapy Device for the pre-treatment of calcified, stenotic de novo coronary artery lesions .
详细描述
The approved IVL devices are based on balloon design, and the biggest limitation is the crossability, especially in the severe stenosis lesions.
Coronary Forward IVL Catheter allow the catheter to modify calcium in tight, difficult to cross lesions to increase the compliance of the vessel and allow further crossing of the device or additional treatment.
This trial consists of two parts:
Part 1 (RCT part): this part is a prospective, multicenter, randomized controlled, study in subjects with moderate-to-severe calcification.180 eligible subjects are planned to enroll .
Part 2 (Single-arm part):This part is a single-arm study in subjects with calcified lesions that are Chronic Total Occlusions (CTOs)(with minimum 30 subjects).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Inclusion Criteria:
- •Age ≥18 years, male or female.
- •Primary coronary artery disease (with evidence of asymptomatic myocardial ischemia, stable/unstable angina, or old MI) scheduled for non-emergent PCI.
- •Pre-procedure Left Ventricular Ejection Fraction (LVEF) ≥30%.
- •Voluntarily participate in this study and sign Informed Consent Form (ICF), willing to comply with study procedures and follow-up.
- •Angiographic Inclusion Criteria:
- •Target lesion is de novo calcified stenotic coronary lesion with no prior intervention.
- •Target lesion reference vessel diameter is 2.5-4.0 mm.
- •Target lesion meets ONE of the following:
- •RCT part: Moderate-to-severe calcification AND stenosis ≥90% and <100% (length ≤60 mm). (Moderate Calcification: Clearly visible high-density shadows during cardiac motion; Severe Calcification: Clearly visible high-density shadows visible without cardiac motion).
- •Single-arm part: Calcified lesion AND Chronic Total Occlusion (CTO) (length ≤20 mm).
- •Guidewire positioned in the true lumen distal to the target lesion and not in the subintimal space prior to device use.
排除标准
- •General Exclusion Criteria
- •Planning use of scoring/cutting balloons, Excimer Laser Coronary Atherectomy (ELCA), or Coronary Intravascular Lithotripsy balloons for calcified lesion modification prior to study device use.
- •NYHA Class III or IV.
- •Currently on dialysis or serum creatinine level >2.5 mg/dL (or 221 µmol/L).
- •Severe coagulation disorder (platelet count <100×10⁹/L).
- •Hyperviscosity diseases (e.g., polycythemia vera, platelet count >750×10⁹/L).
- •Cardiac shock with clinical signs or symptoms.
- •Active systemic infection.
- •Moderate-to-severe anemia (hemoglobin <90 g/L).
- •Acute Myocardial Infarction within 1 month prior to procedure.
- •Stroke or Transient Ischemic Attack (TIA) within 3 months prior to procedure.
- •Active gastrointestinal ulcer or bleeding within 3 months prior to procedure.
- •Expected life expectancy <12 months as assessed by the investigator.
- •Known intolerance to antiplatelet or anticoagulant therapy.
- •Known allergy to study device components or contrast media.
- •Known pregnancy or lactation (female subjects).
- •Participating or planning to participate in another drug or device clinical trial.
- •Other conditions deemed unsuitable for participation by the investigator
- •Angiographic Exclusion Criteria:
- •Unprotected left main coronary artery disease (stenosis >50%).
- •Serious angiographic complication in the target vessel prior to study device use.
- •Presence of thrombus or suspected thrombus in the target vessel.
- •Aneurysm within 10 mm of the target lesion in the target vessel.
- •Presence of other lesions with stenosis >50% within the target vessel.
- •CTO lesion with excessive tortuosity (>45°) or length >20 mm.
- •Stent implanted within 5 mm proximal or distal to the target lesion.
- •Target lesion accessible only via saphenous vein graft (SVG) or arterial graft.
- •Failure of guidewire to successfully cross the target lesion.
- •Planned use of Antegrade Dissection Re-entry (ADR), Retrograde Wiring (RW), or Retrograde Dissection Re-entry (RDR) techniques
结局指标
主要结局
Rate of Device Success
时间窗: immediately after IVL intervention
Freedom from Major Adverse Cardiovascular Events (MACE) within 30 days post-procedure
时间窗: 30-day after the procedure
次要结局
- Incidence of Target Lesion Failure(during procedure, at discharge (up to 7 days after the procedure), 30 days after the procedure, 180 days after the procedure)
- Incidence of Patient-Oriented Cardiovascular Endpoint(during procedure, at discharge (up to 7 days after the procedure), 30 days after the procedure, 180 days after the procedure)
- Incidence of Device Deficiencies(immediately after the prcedure)
- Excellent rate of device performance evaluation(Immediately after the procedure)
- Rate of Technical Success(immediately after the procedure)
- Rate of Angiographic Success(Peri-procedural)
- Rate of Procedural Success(at discharge/up to 7 days after the procedure)
- Incidence of Adverse Events and Serious Adverse Events(through study completion, 180 days after the procedure)
- Incidence of serious angiographic complications(immediately after the procedure)
- Incidence of MACE(during procedure, at discharge (up to 7 days after the procedure) ,180 days after the procedure)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Coronary Crossing System in Patients With Coronary Chronic Total OcclusionsChronic Total Occlusion of Coronary ArteryNCT05813704Shanghai MicroPort Rhythm MedTech Co., Ltd.159
已完成
不适用
Coronary Intravascular Lithotripsy System in Patients With Coronary Artery Calcification (VIGOUR)Coronary Artery CalcificationNCT05818098Shanghai MicroPort Rhythm MedTech Co., Ltd.189
尚未招募
不适用
The First-In-Man Use of Coronary Sinus Balloon Pump in STEMI Patients Treated by Primary PCISTEMINCT07082153Shanghai MicroPort Rhythm MedTech Co., Ltd.10
尚未招募
不适用
Trial for MicroPort's DCBCoronary Artery In-stent RestenosisNCT04386213Shanghai MicroPort Medical (Group) Co., Ltd.216
已完成
不适用
Safety and Effectiveness Study of the Solysafe Septal Occluder in Patients With Atrial Septum Defect and Patent Foramen OvaleAtrial Septal DefectPatent Foramen OvaleNCT00207376Carag AG